Madrigal Pharmaceuticals, Inc. (MDGL)
| Previous close | 217.17 |
| Open | 217.53 |
| Bid | 219.08 x 300 |
| Ask | 220.88 x 200 |
| Day's range | 215.02 - 221.52 |
| 52-week range | 119.76 - 302.68 |
| Volume | |
| Avg. volume | 521,704 |
| Market cap | 4.688B |
| Beta (5Y monthly) | -0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosisIn April 2024, product shipped and first patients received Rezdiffra, the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)On March 5, 2024, announced validation of European Medicines Agency marketing application for resmetirom Raised $690 million in gross p
- GlobeNewswire
Madrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis (NASH), and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent in
- GlobeNewswire
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceut
